[Cardiovascular prevention, primary or secondary, in high risk patients]

J L Richard1, F Delahaye

  • 1Unité 258 INSERM, hôpital Broussais, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|January 19, 1999
PubMed

Insights

Cardiovascular disease prevention advice is more frequently followed in secondary prevention patients. However, risk factor monitoring and adherence to lifestyle changes remain suboptimal across both primary and secondary prevention groups, indicating a need for improved organization.

Area of Science:

  • Cardiology
  • Public Health
  • Preventive Medicine

Background:

  • Coronary artery disease (CAD) management involves preventive strategies.
  • Patient adherence to cardiovascular prevention advice varies significantly.
  • Understanding differences in prevention uptake between primary and secondary prevention is crucial.

Purpose of the Study:

  • To evaluate the advice received and followed for cardiovascular prevention in patients with coronary artery disease.
  • To compare the effectiveness of primary versus secondary prevention strategies in patient adherence and risk factor management.
  • To identify gaps in the diagnosis and follow-up of cardiovascular risk factors.

Main Methods:

  • Consecutive patients admitted for coronary artery disease were divided into two groups: primary prevention (disease < 1 month) and secondary prevention (disease > 6 months).
  • Interrogation focused on cardiovascular prevention advice received and followed, including dietary changes and treatments.
  • Analysis included the follow-up of risk factors like serum cholesterol and glucose levels.

Main Results:

  • Secondary prevention patients showed higher compliance with medical advice and better follow-up of risk factors compared to primary prevention patients.
  • Diagnosis and follow-up of risk factors were incomplete in both groups, with significant percentages of unmeasured cholesterol and glucose levels.
  • While prevention measures were advised to a majority of patients, compliance with diet and cholesterol-lowering drugs was mediocre, with many patients exceeding recommended levels.

Conclusions:

  • Cardiovascular prevention strategies require better organization to improve patient outcomes.
  • Despite better adherence in secondary prevention, overall management of risk factors and patient compliance needs enhancement.
  • The study highlights the need for systematic and comprehensive approaches to cardiovascular risk factor management in clinical practice.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
889
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
443
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
804
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
750
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
726